Home » Healthcare » Pharmaceuticals » India Biopharmaceuticals Contract Manufacturing Market

India Biopharmaceuticals Contract Manufacturing Market By Source (Mammalian, Non-mammalian); By Service (Process Development, Downstream, Upstream, Fill & Finish Operations, Analytical & QC Studies, Packaging & Labelling, Others); By Drug Type (Biologics, Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, Others, Biosimilars); By Type (Drug Substance, Finished Drug Product); By Scale of Operation (Clinical, Commercial); By Therapeutic Area (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
India Biopharmaceuticals Contract Manufacturing Market Size 2023	USD 418.11 million
India Biopharmaceuticals Contract Manufacturing Market, CAGR	17.88%
India Biopharmaceuticals Contract Manufacturing Market Size 2032	USD 1,838.85 million

Market Overview

The India Biopharmaceuticals Contract Manufacturing Market is projected to grow from USD 418.11 million in 2023 to USD 1,838.85 million by 2032, with a compound annual growth rate (CAGR) of 17.88%.

The India biopharmaceuticals contract manufacturing market is driven by factors such as the growing demand for affordable and high-quality drugs, the expansion of biopharmaceutical research, and the increasing shift towards outsourcing manufacturing activities by global pharmaceutical companies. India’s cost-effectiveness, skilled workforce, and strong regulatory framework further bolster its position as a key hub for contract manufacturing. Additionally, advancements in biotechnology and biosimilars, along with a rising focus on personalized medicine, are fueling market growth. The increasing prevalence of chronic diseases, combined with government initiatives to support the biopharmaceutical sector, is also contributing to the market’s expansion. Furthermore, trends such as the adoption of automated and AI-powered manufacturing processes, along with an emphasis on sustainability, are transforming the industry, enabling faster production cycles and improved efficiency, thus attracting more international partnerships and investments in India’s contract manufacturing sector.

India’s biopharmaceuticals contract manufacturing sector spans diverse geographical regions, each contributing uniquely to the market’s growth. The Northern and Western regions stand out as prominent hubs, with advanced infrastructure and a strong presence of pharmaceutical companies. Southern India, with cities like Bengaluru and Hyderabad, is recognized for its robust biotechnology ecosystem and focus on biosimilar production. Meanwhile, the Eastern region is emerging with growing investments in pharmaceutical infrastructure. Key players driving this market include Boehringer Ingelheim GmbH, Lonza, AGC Biologics, Samsung Biologics, Thermo Fisher Scientific, and Catalent, Inc., among others. These companies leverage India’s cost-effective manufacturing capabilities, skilled workforce, and regulatory advancements to expand their production capacities and cater to global demand. Collaborative partnerships and technological advancements further position India as a preferred destination for biopharmaceutical contract manufacturing, ensuring high-quality and efficient production services for international clients.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Insights

The India biopharmaceuticals contract manufacturing market is projected to grow from USD 418.11 million in 2023 to USD 1,838.85 million by 2032, at a CAGR of 17.88%.
Growing demand for biosimilars and biologics globally is driving investments in India’s biopharmaceutical manufacturing sector.
Technological advancements in process development and automation are enhancing production efficiency and product quality.
Key players, including Boehringer Ingelheim, Lonza, and Samsung Biologics, are leveraging India’s cost advantages and skilled workforce.
Stringent regulatory frameworks and compliance requirements remain a significant challenge for manufacturers.
The Western region dominates the market, with strong infrastructure and export capabilities, while the Eastern region is emerging with growing investments.
Increasing global outsourcing trends in biologics manufacturing present significant opportunities for Indian contract manufacturers to expand their presence.

Market Drivers

Growing Demand for Affordable Healthcare

The increasing demand for affordable and high-quality biopharmaceuticals is a significant driver of contract manufacturing in India. As healthcare costs rise globally, pharmaceutical companies are seeking cost-effective production solutions. India, with its competitive labor costs and expertise in large-scale drug production, has emerged as a preferred destination for outsourcing biopharmaceutical manufacturing. For instance, India has over 665 FDA-approved plants, the highest number outside the USA, which underscores its capability in high-quality production. This trend is especially notable in the production of biologics, vaccines, and biosimilars, where affordability plays a crucial role in improving access to life-saving medicines.

Government Support and Regulatory Framework

The Indian government’s support for the biopharmaceutical industry, through initiatives like the National Biopharma Mission and improved regulatory policies, has created a conducive environment for contract manufacturing. For instance, the National Biopharma Mission supports over 100 projects, including more than 150 organizations and 30 MSMEs. The government’s push for innovation, along with a streamlined regulatory framework, facilitates faster approvals for biopharmaceutical products. This has enhanced India’s attractiveness as a destination for global pharmaceutical companies seeking to outsource manufacturing operations. Furthermore, India’s adherence to international quality standards ensures that contract manufacturers can produce biopharmaceuticals that meet global market requirements.

Advancements in Biotechnology and Biosimilars

Advancements in biotechnology, particularly in the development of biosimilars, are boosting the demand for contract manufacturing services in India. The country’s robust research infrastructure and increasing number of biopharmaceutical companies focused on biosimilar development are contributing to this trend. India’s expertise in producing high-quality biosimilars at lower costs is attracting global pharmaceutical companies looking to leverage the country’s manufacturing capabilities. As the biosimilars market continues to grow, India’s contract manufacturers are well-positioned to meet the rising demand for these complex therapies.

Shift Towards Outsourcing and Strategic Partnerships

The growing trend of outsourcing manufacturing functions by global pharmaceutical companies is a key driver of India’s biopharmaceuticals contract manufacturing market. By partnering with Indian contract manufacturers, companies can focus on their core competencies, such as R&D and marketing, while reducing capital expenditures and operational risks. Additionally, the rise in strategic collaborations and partnerships between Indian manufacturers and international companies is facilitating knowledge transfer, enhancing production capabilities, and ensuring a more competitive market presence globally. These partnerships help boost India’s position in the global biopharmaceutical manufacturing supply chain.

Market Trends

Increased Focus on Biotechnology and Biosimilars

A key trend shaping India’s biopharmaceutical contract manufacturing market is the growing focus on biotechnology and biosimilars. With the rising demand for biologics and biosimilars worldwide, India’s biopharmaceutical contract manufacturers are leveraging their expertise to produce these complex products at competitive prices. The country’s well-established infrastructure for biologic drug production, coupled with increasing investments in biosimilar development, positions India as a critical player in the global market. For instance, India has over 95 approved biosimilars in the domestic market, more than any other country. As biosimilars continue to gain traction, Indian manufacturers are increasingly partnering with global pharmaceutical companies to meet this rising demand.

Integration of Advanced Manufacturing Technologies

The adoption of advanced manufacturing technologies is another significant trend in India’s biopharmaceutical contract manufacturing sector. Companies are increasingly incorporating automation, artificial intelligence, and data analytics into their production processes to enhance efficiency, reduce errors, and improve quality control. These technologies allow for faster production cycles, higher throughput, and the ability to scale up operations to meet growing global demand. Furthermore, the implementation of these innovations supports the production of high-quality biopharmaceuticals that meet global regulatory standards, further solidifying India’s reputation as a reliable manufacturing hub.

Sustainability and Green Manufacturing Practices

Sustainability is becoming an essential trend in India’s biopharmaceutical contract manufacturing market. Manufacturers are increasingly focusing on implementing green manufacturing practices, such as reducing energy consumption, minimizing waste, and adopting environmentally friendly production methods. For instance, a study revealed that green manufacturing practices directly and positively affected operational performance in the Indian pharmaceutical industry. This shift is driven by both environmental concerns and the growing demand from global pharmaceutical companies for sustainable production processes. By investing in eco-friendly technologies and adhering to international sustainability standards, Indian contract manufacturers are gaining a competitive edge and meeting the expectations of environmentally conscious stakeholders.

Expansion of Strategic Global Partnerships

A notable trend in India’s biopharmaceutical contract manufacturing market is the expansion of strategic global partnerships. Indian contract manufacturers are increasingly collaborating with multinational pharmaceutical companies to handle the growing demand for biopharmaceutical production. These partnerships allow for knowledge sharing, resource pooling, and enhanced technological capabilities, ultimately improving the global competitiveness of Indian manufacturers. Such collaborations also enable Indian companies to expand their market reach, access new technologies, and strengthen their position in the global supply chain, further driving growth in the sector.

Market Challenges Analysis

Regulatory and Compliance Challenges

One of the primary challenges faced by India’s biopharmaceuticals contract manufacturing sector is navigating complex regulatory frameworks. While India has made significant strides in aligning its regulations with global standards, the approval process for biopharmaceuticals can still be time-consuming and cumbersome. The need to comply with both domestic and international regulatory requirements, such as those set by the U.S. FDA and European Medicines Agency, poses challenges for manufacturers. Ensuring that production facilities adhere to stringent Good Manufacturing Practices (GMP) and meeting the evolving regulatory standards can require significant investments in infrastructure, training, and quality control. For instance, the Central Drugs Standard Control Organization (CDSCO) in India conducts over 200 inspections annually to ensure compliance with GMP. Delays in regulatory approvals or non-compliance can impact timelines and lead to financial losses, especially when dealing with global pharmaceutical companies that demand fast and reliable manufacturing processes.

Intense Competition and Price Pressure

Another significant challenge is the intense competition within the contract manufacturing sector, especially in a market as price-sensitive as India. As the demand for biopharmaceuticals grows globally, many local and international contract manufacturers are vying for market share. This leads to price pressure, with many manufacturers offering lower rates to secure contracts. While cost competitiveness is a major advantage for India, it can also reduce profit margins and hinder investment in innovation, technology, and capacity expansion. Furthermore, the competitive landscape often leads to an oversupply of manufacturing capacity, resulting in underutilized facilities. Indian contract manufacturers must, therefore, find ways to differentiate themselves, such as through superior quality, faster turnaround times, and the adoption of cutting-edge technologies, to stay ahead of the competition.

Market Opportunities

India’s biopharmaceuticals contract manufacturing sector presents significant growth opportunities driven by the increasing global demand for biologics and biosimilars. As more multinational pharmaceutical companies seek cost-effective production solutions, India’s competitive pricing and skilled workforce make it an attractive outsourcing destination. The country’s ability to produce high-quality biopharmaceuticals at lower costs provides a strong value proposition for companies looking to expand their product portfolios, particularly in emerging markets. With an increasing focus on the development of biosimilars, India is well-positioned to become a global leader in this area, offering contract manufacturing services for a variety of biologics and complex therapies. This growing demand presents substantial opportunities for Indian manufacturers to form long-term partnerships with global pharmaceutical firms, expanding their market share and increasing revenue streams.

Additionally, the Indian government’s ongoing support for the biopharmaceutical industry further enhances the sector’s potential for growth. Initiatives such as the National Biopharma Mission and improved regulatory frameworks are providing a conducive environment for innovation and manufacturing excellence. As the global market for biopharmaceuticals continues to evolve, Indian contract manufacturers can leverage advancements in biotechnology, automation, and green manufacturing practices to capitalize on new trends in the industry. Furthermore, the rising prevalence of chronic diseases globally and the need for affordable healthcare solutions open avenues for Indian manufacturers to explore untapped markets. By investing in cutting-edge technologies and strengthening global partnerships, India’s biopharmaceuticals contract manufacturing sector can seize these opportunities to expand and diversify its offerings.

Market Segmentation Analysis:

By Source:

The India biopharmaceuticals contract manufacturing market is segmented by source into mammalian and non-mammalian systems. Mammalian cell cultures are widely used for the production of complex biologics such as monoclonal antibodies, therapeutic proteins, and vaccines due to their ability to replicate human-like post-translational modifications. This segment is expected to dominate the market, driven by the increasing demand for biologics and biosimilars. On the other hand, non-mammalian systems, such as microbial fermentation, are gaining traction due to their cost-effectiveness and faster production times for simpler biologics and vaccines. The adoption of non-mammalian systems is expected to grow, particularly for the production of biosimilars and vaccines, as pharmaceutical companies seek more affordable manufacturing solutions. Both segments have significant potential, with mammalian systems catering to high-value biologics and non-mammalian systems addressing cost-sensitive segments.

By Service:

The market for India biopharmaceuticals contract manufacturing is further segmented based on service offerings, including process development, upstream, downstream, fill & finish operations, analytical & QC studies, packaging & labeling, and others. Process development is crucial for optimizing the production process and ensuring high yield and quality, making it an essential service in the contract manufacturing landscape. Upstream and downstream processes are vital for cell culture development and product purification, respectively, and are integral to biopharmaceutical manufacturing. Fill & finish operations, analytical and QC studies, and packaging & labeling services ensure product safety, compliance, and market readiness. As demand for complex biologics grows, the need for comprehensive service offerings will continue to expand. These segments are vital for contract manufacturers to provide end-to-end solutions, addressing the entire lifecycle of biopharmaceutical production, from initial development to final product distribution.

Segments:

Based on Source:

Mammalian
Non-mammalian

Based on Service:

Process Development
Downstream
Upstream
Fill & Finish Operations
Analytical & QC studies
Packaging & Labelling
Others

Based on Drug Type:

Biologics
Monoclonal antibodies (mAbs)
Recombinant Proteins
Vaccines
Antisense, RNAi, & Molecular Therapy
Others
Biosimilars

Based on Type:

Drug Substance
Finished Drug Product

Based on Scale of Operation:

Clinical
Commercial

Based on Therapeutic Area:

Oncology
Autoimmune Diseases
Cardiovascular Diseases
Infectious Diseases
Others

Based on the Geography:

Northern
Western
Southern
Eastern

Regional Analysis

Northern Region

The Northern region of India holds a significant share of the biopharmaceuticals contract manufacturing market, accounting for approximately 30% of the total market share. The region benefits from its strong pharmaceutical infrastructure, with major hubs in states like Himachal Pradesh, Haryana, and Punjab, which are home to several leading pharmaceutical companies and contract manufacturers. The proximity to key healthcare markets such as Delhi and Chandigarh further strengthens the region’s position in the biopharmaceutical manufacturing sector. Additionally, the availability of skilled labor, along with government initiatives promoting the pharmaceutical industry, contributes to the growth of the biopharmaceuticals contract manufacturing market. This region is particularly well-positioned to cater to the increasing demand for complex biologics and biosimilars, driven by both domestic and international clients.

Western Region

The Western region, encompassing states like Maharashtra, Gujarat, and Rajasthan, commands the largest market share in India’s biopharmaceuticals contract manufacturing sector, contributing to approximately 35% of the overall market. Gujarat, in particular, is a prominent biopharmaceutical manufacturing hub, home to numerous pharmaceutical giants and contract manufacturing organizations. The region’s well-developed infrastructure, coupled with the presence of leading ports and proximity to key markets in the Middle East and Africa, enhances its export capabilities. Furthermore, the Western region benefits from strong government policies that promote biotechnology and pharmaceuticals, fostering the growth of the sector. As the demand for biologics and biosimilars continues to rise, Western India remains a dominant player in the market, attracting both domestic and global investments.

Southern Region

The Southern region, including states like Karnataka, Tamil Nadu, Andhra Pradesh, and Telangana, accounts for approximately 25% of India’s biopharmaceuticals contract manufacturing market. Known for its thriving pharmaceutical ecosystem, the region has seen considerable growth in biopharmaceutical manufacturing, particularly in Bengaluru and Hyderabad, which are recognized as biotechnology and pharmaceutical hubs. The Southern region is also home to several contract manufacturers that focus on process development, analytical services, and the production of biosimilars. The region’s well-established infrastructure, skilled workforce, and strong research and development capabilities create significant opportunities for growth in the biopharmaceuticals contract manufacturing sector. As global pharmaceutical companies continue to outsource production, Southern India’s market share is poised for steady growth, particularly in biologics and complex therapies.

Eastern Region

The Eastern region, consisting of states like West Bengal, Odisha, Bihar, and Jharkhand, currently holds around 10% of India’s biopharmaceuticals contract manufacturing market share. While this region has historically lagged behind other regions in terms of biopharmaceutical manufacturing, it is emerging as an important player due to recent investments in infrastructure and the government’s focus on boosting industrial growth. Kolkata, in particular, is a growing hub for pharmaceutical and biotechnology industries, and its proximity to Southeast Asia and the Middle East presents untapped export potential. As the regional government supports the growth of the biopharmaceutical sector through incentives and policies, the Eastern region is expected to capture a larger share of the market in the coming years, particularly in generic drugs and biosimilars manufacturing.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Boehringer Ingelheim GmbH
Lonza
JRS PHARMA
AGC Biologics
Samsung Biologics
Thermo Fisher Scientific, Inc.
ADMA Biologics, Inc.
Catalent, Inc
Cambrex Corporation
Pfizer Inc.

Competitive Analysis

The India biopharmaceuticals contract manufacturing market is characterized by intense competition among leading players, including Boehringer Ingelheim GmbH, Lonza, AGC Biologics, Samsung Biologics, Thermo Fisher Scientific, Catalent, Inc., and others. These companies leverage India’s cost-efficient manufacturing capabilities and skilled workforce to cater to the growing global demand for biologics and biosimilars. Key players differentiate themselves through technological innovation, robust process development expertise, and adherence to stringent regulatory standards. They also invest significantly in expanding manufacturing capacities and enhancing downstream and upstream processes to meet diverse client requirements. Collaborations and strategic partnerships with domestic manufacturers further strengthen their foothold in the Indian market. For instance, international pharmaceutical giants such as Novartis, Johnson & Johnson, and GlaxoSmithKline have research collaborations in India on various healthcare projects. Despite the competitive advantages, companies face challenges such as price pressures and navigating complex compliance frameworks. However, continuous innovation, coupled with India’s favorable government initiatives, ensures sustained growth opportunities. This competitive landscape drives advancements in technology and processes, positioning India as a key hub for biopharmaceutical contract manufacturing globally.

Recent Developments

In Nov 2024, FUJIFILM Diosynth Biotechnologies signed a multi-year manufacturing agreement with TG Therapeutics for BRIUMVI® production at their new Holly Springs, North Carolina facility.
In October 2024, Lonza extended collaboration with a major biopharmaceutical partner for ADC manufacturing.
In October 2024, Thermo Fisher Scientific launched comprehensive CDMO and CRO drug development solutions..
In July 2024, Rentschler Biopharma opened new state-of-the-art production line in Milford, Massachusetts.
In May 2024, AGC Biologics offering end-to-end biopharmaceutical development and manufacturing capabilities.

Market Concentration & Characteristics

The India biopharmaceuticals contract manufacturing market exhibits a moderately fragmented concentration, with a mix of global giants and emerging domestic players competing for market share. Key players, including Boehringer Ingelheim GmbH, Lonza, Samsung Biologics, and Catalent, Inc., dominate the market due to their advanced manufacturing capabilities, strong regulatory compliance, and extensive client networks. These companies leverage India’s cost advantages and skilled workforce to deliver high-quality biopharmaceuticals, ranging from biosimilars to complex biologics. Meanwhile, domestic manufacturers focus on niche segments and cost-efficient production to carve out their market space, gradually enhancing their technological and operational capacities. The market is characterized by increasing demand for end-to-end manufacturing solutions, driving companies to offer comprehensive services, including process development, analytical testing, fill & finish operations, and packaging. Strategic collaborations and partnerships are key trends, enabling companies to diversify their portfolios and enter new markets. However, the market faces challenges, such as stringent regulatory requirements and pricing pressures, which influence operational strategies. Despite these hurdles, the sector benefits from a robust ecosystem supported by government initiatives, innovation in biologics manufacturing, and a focus on sustainability. These characteristics position India as a pivotal player in the global biopharmaceuticals contract manufacturing landscape.

Report Coverage

The research report offers an in-depth analysis based on Source, Service, Drug Type, Type, Scale of Operation, Therapeutic Area and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The India biopharmaceuticals contract manufacturing market is expected to experience robust growth due to rising global demand for biosimilars and biologics.
Increased outsourcing by global pharmaceutical companies will drive investments in advanced manufacturing facilities in India.
The adoption of cutting-edge technologies like automation and AI will enhance efficiency and production quality in the coming years.
Expansion of end-to-end service offerings by contract manufacturers will cater to the growing demand for integrated manufacturing solutions.
Government initiatives and favorable policies will continue to strengthen India’s position as a global biopharmaceutical manufacturing hub.
Emerging markets in Asia-Pacific and Africa will provide lucrative opportunities for Indian manufacturers to expand their export footprint.
Rising emphasis on sustainability and green manufacturing practices will influence operational strategies in the industry.
Investments in R&D and innovation will enable manufacturers to develop more complex biologics and meet diverse client needs.
Collaboration between domestic and international players will foster technology transfer and boost production capabilities.
Increasing focus on regulatory compliance and quality assurance will reinforce India’s reputation for reliable and high-quality biopharmaceutical production.

CHAPTER NO. 1 : INTRODUCTION 21

1.1.1. Report Description 21

Purpose of the Report 21

USP & Key Offerings 21

1.1.2. Key Benefits for Stakeholders 21

1.1.3. Target Audience 22

1.1.4. Report Scope 22

CHAPTER NO. 2 : EXECUTIVE SUMMARY 23

2.1. India Biopharmaceuticals Contract Manufacturing Market Snapshot 23

2.1.1. India Biopharmaceuticals Contract Manufacturing Market, 2018 – 2032 (USD Million) 24

CHAPTER NO. 3 : INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – INDUSTRY ANALYSIS 25

3.1. Introduction 25

3.2. Market Drivers 26

3.2.1. Rising Number of Biologics 26

3.2.2. Advancements in Manufacturing Technologies 27

3.3. Market Restraints 28

3.3.1. Need for Specialized Facilities and Equipment 28

3.4. Market Opportunities 29

3.4.1. Market Opportunity Analysis 29

3.5. Porter’s Five Forces Analysis 30

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 31

4.1. Company Market Share Analysis – 2023 31

4.1.1. India Biopharmaceuticals Contract Manufacturing Market: Company Market Share, by Volume, 2023 31

4.1.2. India Biopharmaceuticals Contract Manufacturing Market: Company Market Share, by Revenue, 2023 32

4.1.3. India Biopharmaceuticals Contract Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 32

4.1.4. India Biopharmaceuticals Contract Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 33

4.2. India Biopharmaceuticals Contract Manufacturing Market Company Revenue Market Share, 2023 34

4.3. Company Assessment Metrics, 2023 35

4.3.1. Stars 35

4.3.2. Emerging Leaders 35

4.3.3. Pervasive Players 35

4.3.4. Participants 35

4.4. Start-ups /SMEs Assessment Metrics, 2023 35

4.4.1. Progressive Companies 35

4.4.2. Responsive Companies 35

4.4.3. Dynamic Companies 35

4.4.4. Starting Blocks 35

4.5. Strategic Developments 36

4.5.1. Acquisitions & Mergers 36

New Product Launch 36

Regional Expansion 36

4.6. Key Players Product Matrix 38

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 39

5.1. PESTEL 39

5.1.1. Political Factors 39

5.1.2. Economic Factors 39

5.1.3. Social Factors 39

5.1.4. Technological Factors 39

5.1.5. Environmental Factors 39

5.1.6. Legal Factors 39

5.2. Adjacent Market Analysis 39

CHAPTER NO. 6 : INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SOURCE SEGMENT ANALYSIS 40

6.1. India Biopharmaceuticals Contract Manufacturing Market Overview, by Source Segment 40

6.1.1. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Source, 2023 & 2032 41

6.1.2. India Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Source 42

6.1.3. Incremental Revenue Growth Opportunity, by Source, 2024 – 2032 42

6.1.4. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018, 2023, 2027 & 2032 43

6.2. Mammalian 44

6.3. Non-mammalian 45

CHAPTER NO. 7 : INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SERVICE SEGMENT ANALYSIS 46

7.1. India Biopharmaceuticals Contract Manufacturing Market Overview, by Service Segment 46

7.1.1. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Service, 2023 & 2032 47

7.1.2. India Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Service 48

7.1.3. Incremental Revenue Growth Opportunity, by Service, 2024 – 2032 48

7.1.4. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018, 2023, 2027 & 2032 49

7.2. Process Development 50

7.2.1. Downstream 51

7.2.1.1. India Downstream India Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 52

7.2.2. Upstream 53

7.3. Fill & Finish Operations 54

7.4. Analytical & QC studies 55

7.5. Packaging & Labelling 56

7.6. Others 57

CHAPTER NO. 8 : INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY DRUG TYPE SEGMENT ANALYSIS 58

8.1. India Biopharmaceuticals Contract Manufacturing Market Overview, by Drug Type Segment 58

8.1.1. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 59

8.1.2. India Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By End-user 60

8.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 60

8.1.4. India Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 61

8.2. Biologics 62

8.2.1. Monoclonal antibodies (mAbs) 63

8.2.2. Recombinant Proteins 64

8.2.3. Vaccines 65

8.2.4. Antisense, RNAi, & Molecular Therapy 66

8.2.5. Others 67

8.3. Biosimilars 68

CHAPTER NO. 9 : INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY TYPE SEGMENT ANALYSIS 69

9.1. India Biopharmaceuticals Contract Manufacturing Market Overview, by Type Segment 69

9.1.1. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Type, 2023 & 2032 70

9.1.2. India Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Type 71

9.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 71

9.1.4. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018, 2023, 2027 & 2032 72

9.2. Drug Substance 73

9.3. Finished Drug Product 74

CHAPTER NO. 10 : INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SCALE OF OPERATION SEGMENT ANALYSIS 75

10.1. India Biopharmaceuticals Contract Manufacturing Market Overview, by Scale of Operation Segment 75

10.1.1. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 76

10.1.2. India Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Scale of Operation 77

10.1.3. Incremental Revenue Growth Opportunity, by Scale of Operation, 2024 – 2032 77

10.1.4. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 78

10.2. Clinical 79

10.3. Commercial 80

CHAPTER NO. 11 : INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY THERAPEUTIC AREA SEGMENT ANALYSIS 81

11.1. India Biopharmaceuticals Contract Manufacturing Market Overview, by Therapeutic Area Segment 81

11.1.1. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Therapeutic Area, 2023 & 2032 82

11.1.2. India Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Therapeutic Area 83

11.1.3. Incremental Revenue Growth Opportunity, by Therapeutic Area, 2024 – 2032 83

11.1.4. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018, 2023, 2027 & 2032 84

11.2. Oncology 85

11.3. Autoimmune Diseases 86

11.4. Cardiovascular Diseases 87

11.5. Infectious Diseases 88

11.6. Others 89

CHAPTER NO. 12 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – INDIA 90

12.1. India 90

12.1.1. Key Highlights 90

12.1.2. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 91

12.1.3. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 92

12.1.4. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 93

12.1.5. India Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

12.1.6. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 95

12.1.7. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 96

12.1.8. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 97

12.2. UAE 98

12.3. KSA 98

12.4. Israel 98

12.5. Turkey 98

12.6. Iran 98

12.7. Egypt 98

12.8. Nigeria 98

12.9. Algeria 98

12.10. Morocco 98

12.11. Rest of Middle East and Africa 98

CHAPTER NO. 13 : COMPANY PROFILES 99

13.1. Boehringer Ingelheim GmbH 99

13.1.1. Company Overview 99

13.1.2. Product Portfolio 99

13.1.3. Swot Analysis 99

13.1.4. Business Strategy 100

13.1.5. Financial Overview 100

13.2. Lonza 101

13.3. JRS PHARMA 101

13.4. AGC Biologics 101

13.5. Samsung Biologics 101

13.6. Thermo Fisher Scientific, Inc. 101

13.7. ADMA Biologics, Inc. 101

13.8. Catalent, Inc 101

13.9. Cambrex Corporation 101

13.10. Pfizer Inc. 101

List of Figures

FIG NO. 1. India Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 24

FIG NO. 2. Porter’s Five Forces Analysis for India Biopharmaceuticals Contract Manufacturing Market 30

FIG NO. 3. Company Share Analysis, 2023 31

FIG NO. 4. Company Share Analysis, 2023 32

FIG NO. 5. Company Share Analysis, 2023 32

FIG NO. 6. Company Share Analysis, 2023 33

FIG NO. 7. India Biopharmaceuticals Contract Manufacturing Market – Company Revenue Market Share, 2023 34

FIG NO. 8. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Source, 2023 & 2032 41

FIG NO. 9. Market Attractiveness Analysis, By Source 42

FIG NO. 10. Incremental Revenue Growth Opportunity by Source, 2024 – 2032 42

FIG NO. 11. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018, 2023, 2027 & 2032 43

FIG NO. 12. India Biopharmaceuticals Contract Manufacturing Market for Mammalian, Revenue (USD Million) 2018 – 2032 44

FIG NO. 13. India Biopharmaceuticals Contract Manufacturing Market for Non-mammalian, Revenue (USD Million) 2018 – 2032 45

FIG NO. 14. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Service, 2023 & 2032 47

FIG NO. 15. Market Attractiveness Analysis, By Service 48

FIG NO. 16. Incremental Revenue Growth Opportunity by Service, 2024 – 2032 48

FIG NO. 17. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018, 2023, 2027 & 2032 49

FIG NO. 18. India Biopharmaceuticals Contract Manufacturing Market for Process Development, Revenue (USD Million) 2018 – 2032 50

FIG NO. 19. India Biopharmaceuticals Contract Manufacturing Market for Downstream, Revenue (USD Million) 2018 – 2032 51

FIG NO. 20. India Biopharmaceuticals Contract Manufacturing Market for Upstream, Revenue (USD Million) 2018 – 2032 53

FIG NO. 21. India Biopharmaceuticals Contract Manufacturing Market for Fill & Finish Operations, Revenue (USD Million) 2018 – 2032 54

FIG NO. 22. India Biopharmaceuticals Contract Manufacturing Market for Analytical & QC studies, Revenue (USD Million) 2018 – 2032 55

FIG NO. 23. India Biopharmaceuticals Contract Manufacturing Market for Packaging & Labelling, Revenue (USD Million) 2018 – 2032 56

FIG NO. 24. India Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 57

FIG NO. 25. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 59

FIG NO. 26. Market Attractiveness Analysis, By End-user 60

FIG NO. 27. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 60

FIG NO. 28. India Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 61

FIG NO. 29. India Biopharmaceuticals Contract Manufacturing Market for Biologics, Revenue (USD Million) 2018 – 2032 62

FIG NO. 30. India Biopharmaceuticals Contract Manufacturing Market for Monoclonal antibodies (mAbs), Revenue (USD Million) 2018 – 2032 63

FIG NO. 31. India Biopharmaceuticals Contract Manufacturing Market for Recombinant Proteins, Revenue (USD Million) 2018 – 2032 64

FIG NO. 32. India Biopharmaceuticals Contract Manufacturing Market for Vaccines, Revenue (USD Million) 2018 – 2032 65

FIG NO. 33. India Biopharmaceuticals Contract Manufacturing Market for Antisense, RNAi, & Molecular Therapy, Revenue (USD Million) 2018 – 2032 66

FIG NO. 34. India Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 67

FIG NO. 35. India Biopharmaceuticals Contract Manufacturing Market for Biosimilars, Revenue (USD Million) 2018 – 2032 68

FIG NO. 36. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Type, 2023 & 2032 70

FIG NO. 37. Market Attractiveness Analysis, By Type 71

FIG NO. 38. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 71

FIG NO. 39. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018, 2023, 2027 & 2032 72

FIG NO. 40. India Biopharmaceuticals Contract Manufacturing Market for Drug Substance, Revenue (USD Million) 2018 – 2032 73

FIG NO. 41. India Biopharmaceuticals Contract Manufacturing Market for Finished Drug Product, Revenue (USD Million) 2018 – 2032 74

FIG NO. 42. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 76

FIG NO. 43. Market Attractiveness Analysis, By Scale of Operation 77

FIG NO. 44. Incremental Revenue Growth Opportunity by Scale of Operation, 2024 – 2032 77

FIG NO. 45. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 78

FIG NO. 46. India Biopharmaceuticals Contract Manufacturing Market for Clinical, Revenue (USD Million) 2018 – 2032 79

FIG NO. 47. India Biopharmaceuticals Contract Manufacturing Market for Commercial, Revenue (USD Million) 2018 – 2032 80

FIG NO. 48. India Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Therapeutic Area, 2023 & 2032 82

FIG NO. 49. Market Attractiveness Analysis, By Therapeutic Area 83

FIG NO. 50. Incremental Revenue Growth Opportunity by Therapeutic Area, 2024 – 2032 83

FIG NO. 51. India Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018, 2023, 2027 & 2032 84

FIG NO. 52. India Biopharmaceuticals Contract Manufacturing Market for Oncology, Revenue (USD Million) 2018 – 2032 85

FIG NO. 53. India Biopharmaceuticals Contract Manufacturing Market for Autoimmune Diseases, Revenue (USD Million) 2018 – 2032 86

FIG NO. 54. India Biopharmaceuticals Contract Manufacturing Market for Cardiovascular Diseases, Revenue (USD Million) 2018 – 2032 87

FIG NO. 55. India Biopharmaceuticals Contract Manufacturing Market for Infectious Diseases, Revenue (USD Million) 2018 – 2032 88

FIG NO. 56. India Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 89

FIG NO. 57. India Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 90

List of Tables

TABLE NO. 1. : India Biopharmaceuticals Contract Manufacturing Market: Snapshot 23

TABLE NO. 2. : Drivers for the India Biopharmaceuticals Contract Manufacturing Market: Impact Analysis 26

TABLE NO. 3. : Restraints for the India Biopharmaceuticals Contract Manufacturing Market: Impact Analysis 28

TABLE NO. 4. : India Downstream India Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 52

TABLE NO. 5. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 91

TABLE NO. 6. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 91

TABLE NO. 7. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 92

TABLE NO. 8. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 92

TABLE NO. 9. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 93

TABLE NO. 10. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 93

TABLE NO. 11. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

TABLE NO. 12. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

TABLE NO. 13. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 95

TABLE NO. 14. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 95

TABLE NO. 15. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 96

TABLE NO. 16. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 96

TABLE NO. 17. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 97

TABLE NO. 18. : India Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 97

Frequently Asked Questions

What is the current size of the India Biopharmaceuticals Contract Manufacturing Market?

The India Biopharmaceuticals Contract Manufacturing market was valued at USD 418.11 million in 2023 and is projected to grow to USD 1,838.85 million by 2032, with a compound annual growth rate (CAGR) of 17.88%.

What factors are driving the growth of the India Biopharmaceuticals Contract Manufacturing Market?

Key factors driving growth include the increasing demand for affordable and high-quality biopharmaceuticals, advancements in biotechnology and biosimilars, government initiatives such as the National Biopharma Mission, and the shift toward outsourcing by global pharmaceutical companies. India’s cost-effectiveness and skilled workforce further bolster its position as a preferred destination for contract manufacturing.

What are the key segments within the India Biopharmaceuticals Contract Manufacturing Market?

The market is segmented by source (mammalian and non-mammalian), service (process development, downstream, upstream, fill & finish operations, analytical & QC studies, packaging & labeling, and others), drug type (biologics, monoclonal antibodies, vaccines, biosimilars, etc.), type (drug substance and finished drug product), scale of operation (clinical and commercial), and therapeutic area (oncology, autoimmune diseases, cardiovascular diseases, infectious diseases, and others).

What are some challenges faced by the India Biopharmaceuticals Contract Manufacturing Market?

Challenges include navigating complex regulatory frameworks and ensuring compliance with both domestic and international standards, such as those set by the U.S. FDA and EMA. Intense competition and price pressures also pose challenges, requiring manufacturers to balance cost-efficiency with innovation and quality assurance.

Who are the major players in the India Biopharmaceuticals Contract Manufacturing Market?

Major players include Boehringer Ingelheim GmbH, Lonza, AGC Biologics, Samsung Biologics, Thermo Fisher Scientific, Catalent, Inc., and others. These companies leverage India’s manufacturing capabilities and regulatory advancements to cater to the growing global demand for biopharmaceuticals.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –